Feature | May 13, 2013| Dave Fornell

ECMO May Become the pVAD of the Future

There is a growing trend in the use of small, portable extracorporeal membrane oxygenation (ECMO) systems for hemodynamic support. In years past, ECMO systems were a tool of the operating room, primarily for bypass surgery. Older systems required a perfusionist to watch the machine 24 hours a day while it was in operation. Today’s ECMOs use consoles that are much easier to use and do not require a full-time person to monitor. Also, as the technology has been miniaturized, simplified and now uses a percutaneous access system, ECMOs are being used outside the OR, including the cath lab, when a large amount of support is needed that cannot be provided by IABPs or pVADs. 

“These are definitely being put in the cath lab more and will see increasing use in the cath lab in the future ­— that will become the norm,” said Alan L. Gass, M.D., medical director, heart failure, heart transplantation and mechanical circulatory support, Westchester Heart and Vascular, and associate professor of medicine, New York Medical College. 

“We have seen that trend and we are helping drive it,” said Luca Lombardi, M.D., chief medical officer, Maquet Cardiovascular. “The technology has evolved tremendously over the past few years to reduce the trauma to the patient. Just 10 years ago we had to do a full surgical exposure to access the vessels, but today the external diameter of the canula is percutaneous, between 1.2 mm for pediatrics and up to 5 mm for adults.”

Gass has experience with both the Maquet CardioHelp and Thoratec CentriMag extracorporeal circulatory support devices. 

The CardioHelp is the world’s smallest circulatory and/or pulmonary support system, weighing just 22 pounds. It can be carried by one person and can be used inside or outside the hospital, including for patient transport. It offers an easy-to-use, touch-screen console interface and plug-and-play setup. Gass said the system offers 3 to 5 lpm of flow, so in patients who need more support than an IABP, he often uses this system as the next step up. 

“It’s a great little system with everything you need put into a small package,” Gass said. 

His only criticism of the CardioHelp is the inability to see if clots are forming in the oxygenator. 

The CentriMag pump is also very small, lightweight and easily transportable. Thoretec says the system can deliver up to 9.9 lpm of flow. The pump has no bearings, but instead uses magnetic levitation, which the vendor says reduced hemolysis (destruction of red blood cells) and the likelihood of mechanical pump failure. 

Related Content

FDA Class I Recall Issued for Medtronic HeartWare HVAD Pump
News | Ventricular Assist Devices (VAD) | May 29, 2020
May 29, 2020 — Medtronic is recalling its HeartWare HVAD...
Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...